Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13143574 | 0.85 | MAPT (0.39) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL23143030 | 0.85 | MAPT (0.39) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL12229221 | 0.83 | MAPT (0.52) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL7615672 | 0.83 | MAPT (0.52) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL13142863 | 0.81 | MAPT (0.37) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL23142965 | 0.80 | MAPT (0.36) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL18177133 | 0.79 | METAP2 (0.31) | METAP2METAP1 | |
| SCHEMBL22872339 | 0.79 | METAP2 (0.31) | METAP2METAP1 | |
| SCHEMBL14347469 | 0.79 | METAP2 (0.31) | METAP2METAP1 | |
| SCHEMBL17663575 | 0.78 | METAP2 (0.33) | METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348671-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG SYNERGIST, AND PREPARATION METHOD THEREFOR, AND USE THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348671-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG SYNERGIST, AND PREPARATION METHOD THEREFOR, AND USE THEREOF | THEM6, WEE1, SLC10A1 | MAPT 1048/4885KDM4E 3313/4885THRB 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.